文献速递消化道出血肝病消化内镜

氨甲环酸用于肝硬化患者上消化道出血:一项随机对照试验

Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis: A randomized controlled trial.
PubMed 文献 · Hepatology · 2024-03-05

研究纳入600例Child-Turcotte-Pugh B或C级肝硬化合并上消化道出血患者,随机分为氨甲环酸组(n=300)和安慰剂组(n=300)。主要结局5天治疗失败率氨甲环酸组为6.3%(19/300),安慰剂组为13.3%(40/300),P=0.006;但5天和6周死亡率两组相似。

要点

  • 氨甲环酸组5天治疗失败率6.3%(19/300),安慰剂组13.3%(40/300),P=0.006。
  • 首次食管静脉套扎术后EVL部位出血导致5天失败:氨甲环酸组4.9%(11/222),安慰剂组原文写作1212.0%(27/225),P=0.005。
  • 5天和6周死亡率氨甲环酸组与安慰剂组相似。

核心结论

  • 氨甲环酸可显著降低晚期肝硬化(Child-Turcotte-Pugh B或C级)合并上消化道出血患者第5天治疗失败率及第5天至6周再出血预防失败率,机制为预防EVL部位出血。

研究设计与样本

  • 随机对照试验,纳入600例晚期肝硬化(Child-Turcotte-Pugh B或C级)合并上消化道出血患者,随机分为氨甲环酸组(n=300)和安慰剂组(n=300)。

主要发现

  • 5天治疗失败率氨甲环酸组为6.3%(19/300),安慰剂组为13.3%(40/300),P=0.006。
  • 首次食管EVL术后EVL部位出血导致5天失败率氨甲环酸组为4.9%(11/222),安慰剂组原文写作1212.0%(27/225),P=0.005。
  • 5天和6周死亡率氨甲环酸组与安慰剂组相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with Child-Turcotte-Pugh class B and C cirrhosis with upper gastrointestinal bleeding (UGIB) have systemic as well as localized (in the mucosa of the esophagus and stomach) fibrinolysis. The aim of this study was to evaluate the efficacy and safety of tranexamic acid in the treatment of acute UGIB in patients with cirrhosis. APPROACH AND RESULTS: A total of 600 patients with advanced liver cirrhosis (Child-Turcotte-Pugh class B or C) presenting with UGIB were randomly allocated to either the tranexamic acid (n=300) or the placebo group (n=300). The primary outcome measure was the proportion of patients developing 5-day treatment failure. Failure to control bleeding by day 5 was seen in 19/300 (6.3%) patients in the tranexamic acid group and 40/300 (13.3%) patients in the placebo group ( p =0.006). Esophageal endoscopic variceal ligation (EVL) site as a source of failure to control bleeding by day 5 among patients undergoing first-time esophageal EVL (excluding patients with a previous post-EVL ulcer as a source of bleed) was seen in 11/222 (4.9%) patients in the tranexamic acid group and 27/225 (1212.0%) patients in the placebo group ( p =0.005). However, 5-day and 6-week mortality was similar in the tranexamic acid and placebo groups. CONCLUSIONS: Tranexamic acid significantly reduces the failure to control bleeding by day 5 and failure to prevent rebleeding after day 5 to 6 weeks in patients with advanced liver cirrhosis (Child-Turcotte-Pugh class B or C) presenting with UGIB, by preventing bleeding from the EVL site.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kumar M, Venishetty S, Jindal A, et al. Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis: A randomized controlled trial. Hepatology. 2024. PMID: 38441903. doi:10.1097/HEP.0000000000000817

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。